A Study of AL58805 in Patients With Advanced Tumors

NCT07179081 | Recruiting Phase 1

• 1 other identifier: AL58805-CN-001B
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

This Phase I clinical trial is a dose-escalation, multicenter study in patients with advanced solid tumors. It includes tolerance studies of sequential multiple oral doses of AL58805 and pharmacokinetic studies of single and multiple doses, analyzing the tolerance range of multiple doses, observing the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) in solid tumor patients, and assessing the reversibility of toxicity and the relationship between toxicity and dose.

Conditions

Advanced Tumors

Outcome Measures

Primary Outcomes (1)

• Dose-limiting toxicity

  It is the evaluation of dose-limiting toxicity (DLT) and general safety that occur during the single administration and the first continuous administration treatment cycle. The evaluation depends on the criteria for DLT. The parameters used to assess safety in this study include adverse events, physical examinations, vital signs (especially blood pressure), and laboratory tests (including serum chemistry, hematology, urine routine, and electrocardiogram (ECG), etc.)

  From signing the ICF until 28 days after the first dosing

Secondary Outcomes (7)

• Tmax

  Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol.

• Css_min

  Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol.

• Css_av

  Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol.

• T1/2

  Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol.

• CL or CL/F

  Conduct testing within 1 month after all subjects collect plasma samples at all time points required by the protocol.

Study Arms (1)

AL58805

EXPERIMENTAL

20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；

Drug: AL58805

Interventions

AL58805 DRUG

Oral,Multiple administrations, once or twice daily（20mg 、40mg QD; 20mg 、30mg、40mg、50mg、60mg BID；）

AL58805

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must meet all the following criteria to be eligible:
• Patients with histologically or cytologically confirmed advanced tumors (including but not limited to lymphoma, colorectal cancer, breast cancer, pancreatic cancer, lung cancer, head and neck cancer, bladder cancer, cholangiocarcinoma) who lack effective standard treatment options or have failed conventional standard treatments (due to disease progression or intolerable toxicity).
• Previous treatment with cytotoxic chemotherapy, with at least 4 weeks between the end of chemotherapy and enrollment, and recovery from previous chemotherapy toxicities to ≤ Grade 1 (except alopecia).
• Must have measurable lesions according to RECIST 1.1 criteria.
• Major organ function: Absolute neutrophil count (ANC) ≥1.5 × 10\^9/L (1500/mm3), platelets ≥75 × 10\^9/L, hemoglobin ≥9g/dL. Serum total bilirubin ≤2 × upper limit of normal (ULN). Serum creatinine ≤1.5 × ULN or creatinine clearance ≥50 mL/min. For patients without liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 × ULN; for patients with liver metastases, ALT and AST ≤5 × ULN. Left ventricular ejection fraction (LVEF) ≥ lower limit of normal.
• Age ≥18 years; ECOG performance status (PS) 0 or 1.
• Expected survival time of at least 12 weeks.
• No malabsorption or other gastrointestinal diseases affecting drug absorption.
• For women of childbearing potential: Negative pregnancy test before treatment and use of medically approved contraception during treatment and for 3 months after treatment ends. Must be non-lactating.
• For male subjects: Surgical sterilization or use of medically approved contraception during treatment and for 3 months after treatment ends.
• Ability to understand and sign informed consent.

You may not qualify if:

• Subjects meeting any of the following criteria will be excluded:
• Known allergy to the investigational drug or drugs with similar chemical structures.
• Use of unapproved drugs or other investigational drugs within 30 days before enrollment.
• Status of the organ systems:
• Current symptomatic brain metastases or leptomeningeal metastases, or central nervous system (CNS) metastases with uncontrolled symptoms within 8 weeks of first dose.
• Uncontrolled hypertension requiring multiple medications (Grade 2 or higher). Acute myocardial infarction within 6 months. Current arrhythmias (e.g., long QT syndrome, Bazett's corrected QTc ≥480 ms). NYHA Class III or IV heart failure. Poorly controlled diabetes. Any unstable systemic disease (including active infection, angina, hepatic, renal, or metabolic diseases).
• Presence of ascites or pleural effusion (CTCAE 5.0 ≥ Grade 2). Persistent diarrhea (average watery stools ≥1 per day). History of definite neurological or psychiatric disorders (e.g., epilepsy, dementia, mood disorders).
• Patients with active/venous thrombosis events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis and pulmonary embolism.
• Previous treatment with the investigational drug.
• Concurrent other anti-tumor treatments. Other conditions deemed unsuitable by the investigator.

Sponsors & Collaborators

• Advenchen Laboratories Nanjing Ltd.: lead

Study Sites (1)

Hunan Cancer Hospital

Changsha, Hunan, 410013, China

RECRUITING

Study Officials

• Dongfang Li

  Hunan Cancer Hospital

  PRINCIPAL INVESTIGATOR

• Yongchang Zhang

  Hunan Cancer Hospital

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Li Sha Qi

CONTACT

025-52896159; qilisha@advenchen.com.cn

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: SCREENING
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 5, 2025
• First Posted: September 17, 2025
• Study Start: December 20, 2020
• Primary Completion: January 26, 2026
• Study Completion: January 26, 2026
• Last Updated: September 17, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)